Treatment of early stage chronic hepatitis C virus infection

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Expert Review of Clinical Pharmacology

• Publication date

  2018-03-09

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/17512433.2018.1447923PMID 29498556
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Hepatitis C in Patients With Minimal or No Hepatic Fibrosis: The Impact of Treatment and Sustained Virologic Response on Patient-Reported Outcomes

  2018cited by this paper
• Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe.

  2018cited by this paper
• Is global elimination of HCV realistic?

  2018cited by this paper
• Report from the International Conference on Viral Hepatitis (ICVH) – Chicago, October 2017

  2018cited by this paper
• Non-healthcare costs of hepatitis C: a systematic review

  2018cited by this paper
• The next wave of hepatitis C virus: The epidemic of intravenous drug use

  2018cited by this paper
• Efficacy and safety of new direct antiviral agents in hepatitis C virus–infected patients with diffuse large B‐cell non‐Hodgkin's lymphoma

  2018cited by this paper
• Hepatitis C virus clearance by direct‐acting antiviral treatments and impact on insulin resistance in chronic hepatitis C patients

  2018cited by this paper
• Significant improvement of glycemic control in diabetic patients with HCV infection responding to direct‐acting antiviral agents

  2018cited by this paper
• Report from the International Conference on Viral Hepatitis - 2017.

  2018cited by this paper
• Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C

  2017cited by this paper
• Virologic, Clinical, and Immune Response Outcomes of Patients With Hepatitis C Virus–Associated Cryoglobulinemia Treated With Direct‐Acting Antivirals

  2017cited by this paper
• HCV clearance by direct-acting antiviral treatments reverses insulin resistance in chronic hepatitis C patients

  2017cited by this paper
• Hepatitis C virus treatment as prevention in an extended network of people who inject drugs in the USA: a modelling study.

  2017cited by this paper
• Role of IL28B genotype in the liver stiffness increase in untreated patients with chronic hepatitis C.

  2017cited by this paper
• The present and future disease burden of hepatitis C virus infections with today's treatment paradigm: Volume 4

  2017cited by this paper
• Efficacy and prognosis of antiviral therapy on hepatitis C following treatment of lymphoma in HCV-positive diffuse large-cell lymphoma

  2017cited by this paper
• A clinician’s guide to the cost and health benefits of hepatitis C cure assessed from the individual patient perspective

  2017cited by this paper
• Virological and Clinical Response to Interferon-Free Regimens in Patients with HCV-Related Mixed Cryoglobulinemia: Preliminary Results of a Prospective Pilot Study.

  2017cited by this paper
• Ongoing liver inflammation in patients with chronic hepatitis C and sustained virological response

  2017cited by this paper
• EASL Recommendations on Treatment of Hepatitis C 2016.

  2017cited by this paper
• Estimating cost-effectiveness associated with all-oral regimen for chronic hepatitis C in China

  2017cited by this paper
• Public health impact of comprehensive hepatitis C screening and treatment in the French baby-boomer population

  2017cited by this paper
• Clinical Findings of HCV Chronic Infection in Undocumented Immigrants and Low-Income Refugees in Three Areas of Southern Italy.

  2017cited by this paper
• Effectiveness of Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir in Hemodialysis Patients With Hepatitis C Virus Infection and Advanced Liver Fibrosis: Case Reports.

  2017cited by this paper
• Patient-reported outcomes with direct-acting antivirals for the treatment of chronic hepatitis C: current knowledge and outstanding issues

  2017cited by this paper
• Blue-Print for Elimination of Hepatitis C Viral Infection: One Step Closer.

  2017cited by this paper
• Direct-acting Antivirals for Hepatitis C Virus in Patients on Maintenance Dialysis

  2017cited by this paper
• Hepatitis C in pregnancy: screening, treatment, and management.

  2017cited by this paper
• Epidemiology of hepatitis C virus and genotype distribution in immigrants crossing to Europe from North and sub-Saharan Africa.

  2016cited by this paper
• Hypoglycemia in a diabetic patient during hepatitis C therapy

  2016cited by this paper
• Hepatitis C as a risk factor for carotid atherosclerosis – a systematic review

  2016cited by this paper
• Optimizing HCV treatment - Moving beyond the cost conundrum.

  2016cited by this paper
• Value of Treating All Stages of Chronic Hepatitis C: A Comprehensive Review of Clinical and Economic Evidence

  2016cited by this paper
• Hepatitis C virus infection, and neurological and psychiatric disorders – A review

  2016cited by this paper
• Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: Results from ASTRAL-1 placebo-controlled trial.

  2016cited by this paper
• Treatment of hepatitis C virus–associated mixed cryoglobulinemia with direct‐acting antiviral agents

  2016cited by this paper
• Hepatitis C infection: A multi-faceted systemic disease with clinical, patient reported and economic consequences.

  2016cited by this paper
• Rapid decline of fasting glucose in HCV diabetic patients treated with direct-acting antiviral agents.

  2016cited by this paper
• Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treatment-Naive Population.

  2016cited by this paper
• Effects of Viral Eradication With Ledipasvir and Sofosbuvir, With or Without Ribavirin, on Measures of Fatigue in Patients With Chronic Hepatitis C Virus Infection.

  2016cited by this paper
• Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study.

  2016cited by this paper
• Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease.

  2016cited by this paper
• Host - hepatitis C viral interactions: The role of genetics.

  2016cited by this paper
• Chronic hepatitis C virus infection, a new cardiovascular risk factor?

  2016cited by this paper
• Hepatitis C virus and cardiovascular: A review

  2016cited by this paper
• Extrahepatic manifestations of chronic hepatitis C virus infection

  2016influential reference
• Depression and Chronic Hepatitis C (CH-C): A Common and Costly Association: 2085

  2015cited by this paper
• The estimated future disease burden of hepatitis C virus in the Netherlands with different treatment paradigms.

  2015cited by this paper
• Modeling the Health and Economic Burden of Hepatitis C Virus in Switzerland

  2015cited by this paper
• P0709 : Survival of patients infected by chronic hepatitis c and f0f1 fibrosis at baseline after a 15 years follow-up

  2015cited by this paper
• Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study.

  2015cited by this paper
• Cryoglobulinemia Vasculitis.

  2015cited by this paper
• Long‐term effect of HCV eradication in patients with mixed cryoglobulinemia: A prospective, controlled, open‐label, cohort study

  2015cited by this paper
• The Seroprevalence of Hepatitis C Antibodies in Immigrants and Refugees from Intermediate and High Endemic Countries: A Systematic Review and Meta-Analysis

  2015cited by this paper
• Treatment with ledipasvir and sofosbuvir improves patient‐reported outcomes: Results from the ION‐1, ‐2, and ‐3 clinical trials

  2015cited by this paper
• The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies

  2015cited by this paper
• Towards eradication of hepatitis C virus from dialysis units.

  2015cited by this paper
• A Systematic Review Assessing the Impact of Chronic Hepatitis C on Health-Related Quality of Life and Patient-Reported Outcomes: 611

  2014cited by this paper
• The Changing Burden of Hepatitis C Virus Infection in the United States: Model-Based Predictions

  2014cited by this paper
• The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm

  2014cited by this paper
• Cerebral MR spectroscopy and patient-reported men- tal health outcomes in hepatitis C genotype 1 naïve patients treated with ledipasvir and sofosbuvir

  2014cited by this paper
• Multiple Factors Predict Physical Performance in People with Chronic Liver Disease

  2014influential reference
• Impact of emerging hepatitis C virus treatments on future needs for liver transplantation in France: a modelling approach.

  2014cited by this paper
• Barrett's Esophagus Suspected at Endoscopy but No Specialized Intestinal Metaplasia on Biopsy, What's Next?

  2014cited by this paper
• Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C‐related liver disease and costs in Australia

  2014cited by this paper
• Extrahepatic manifestations of chronic hepatitis C virus infection.

  2014cited by this paper
• Hepatitis C Virus Infection and Risk of Stroke: A Systematic Review and Meta-Analysis

  2013cited by this paper
• Associations of chronic hepatitis C with metabolic and cardiac outcomes

  2013cited by this paper
• Hepatitis C virus infection, mixed cryoglobulinemia, and kidney disease.

  2013cited by this paper
• Impact of hepatitis C on survival in dialysis patients: a link with cardiovascular mortality?

  2012cited by this paper
• Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study.

  2012cited by this paper
• Does Hepatitis C Virus Infection Increase Risk for Stroke? A Population-Based Cohort Study

  2012cited by this paper
• Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.

  2012cited by this paper
• Management of hepatitis C virus infection recurrence after liver transplantation: an overview.

  2011cited by this paper
• Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews.

  2011cited by this paper
• Prognostic factors in patients with hepatitis C virus infection and systemic vasculitis.

  2011cited by this paper
• HCV infection and the incidence of CKD.

  2011cited by this paper
• Association of hepatitis C and B virus infection with CKD in an endemic area in Taiwan: a cross-sectional study.

  2010cited by this paper
• Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium.

  2008cited by this paper
• Increased all-cause, liver, and cardiac mortality among hepatitis C virus-seropositive blood donors.

  2008cited by this paper
• Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis.

  2008cited by this paper
• The impact of hepatitis C virus coinfection on HIV-related kidney disease: a systematic review and meta-analysis

  2008cited by this paper
• Hepatitis C virus infection and the risk of coronary disease.

  2008cited by this paper
• Treatment of hepatitis C-associated mixed cryoglobulinemia vasculitis

  2008cited by this paper
• Hepatitis C virus infection and the prevalence of renal insufficiency.

  2007cited by this paper
• Viral hepatitis and proteinuria in an area endemic for hepatitis B and C infections: another chain of link?

  2006cited by this paper
• Hepatitis C Virus and Risk of Lymphoma and Other Lymphoid Neoplasms: A Meta-analysis of Epidemiologic Studies

  2006cited by this paper
• Impact of hepatitis C on health related quality of life: A systematic review and quantitative assessment

  2005cited by this paper
• Relationship between hepatitis C and microalbuminuria: results from the NHANES III.

  2005cited by this paper
• Cognitive function in hepatitis C patients with advanced fibrosis enrolled in the HALT-C trial.

  2005cited by this paper
• Effect of hepatitis C virus infection on the risk of non‐Hodgkin's lymphoma: A meta‐analysis of epidemiological studies

  2004cited by this paper
• B‐cell non‐Hodgkin's lymphoma and hepatitis C virus infection: A systematic review

  2004cited by this paper
• Prevalence of hepatitis C virus infection in B-cell non-Hodgkin's lymphoma: systematic review and meta-analysis.

  2003cited by this paper
• Extrahepatic manifestations of hepatitis C among United States male veterans

  2002cited by this paper
• Lymphotropic virus infection of peripheral blood mononuclear cells in B-cell non-Hodgkin's lymphoma.

  1997cited by this paper
• Non-Hodgkin's lymphoma: possible role of hepatitis C virus.

  1994cited by this paper
• Non-Hodgkin's Lymphoma: Possible Role of Hepatitis C Virus

  1994cited by this paper

• Long-term benefit of DAAs on gut dysbiosis and microbial translocation in HCV-infected patients with and without HIV coinfection

  2023cites this paper
• Improvement of Gut Diversity and Composition after Direct-Acting Antivirals in HCV-Infected Patients with or without HIV Coinfection.

  2021cites this paper
• Hepatitis C virus infection and tobacco smoking - joint health effects and implications for treatment of both: A systematic review

  2021cites this paper
• Improvement of Gut Diversity and Composition After Direct-Acting Antivirals in Hepatitis C Virus–Infected Patients With or Without Human Immunodeficiency Virus Coinfection

  2021cites this paper
• Circular RNA hsa_circ_0004812 impairs IFN-induced immune response by sponging miR-1287-5p to regulate FSTL1 in chronic hepatitis B

  2020cites this paper
• Perspectives on HCV Cure

  2019cites this paper
• Bayesian compartmental models for zoonotic visceral leishmaniasis in the Americas

  2019cites this paper
• Eight weeks of Paritaprevir/r/Ombitasvir + Dasabuvir in HCV genotype 1b with mild‐moderate fibrosis: Results from a real‐world cohort

  2018cites this paper